Obesity pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A comparator gap appears only when the source states that gap.
ClassNone selected
MechanismNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
299 of 2118 arms with a reported figure. Choose arms to narrow the chart.
Change in body weight from baseline, %
Source: Cited trial source. A line uses only weeks that source states. One week is a point, not a line from zero.
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Semaglutide 2.4 mg, STEP 1, one timepoint
- Semaglutide Semaglutide placebo, STEP 1, one timepoint
- Semaglutide 7.2 mg, STEP UP, one timepoint
- Semaglutide 2.4 mg, STEP UP, one timepoint
- Semaglutide Placebo, STEP UP, one timepoint
- Semaglutide Semaglutide, STEP 4, one timepoint
- Semaglutide Placebo, STEP 4, one timepoint
- Tirzepatide Placebo, SURMOUNT-1, one timepoint
- Tirzepatide 5 mg, SURMOUNT-1, one timepoint
- Tirzepatide 10 mg, SURMOUNT-1, one timepoint
- Tirzepatide 15 mg, SURMOUNT-1, one timepoint
- Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg, REDEFINE 1, one timepoint
- Cagrilintide/semaglutide Placebo s.c., REDEFINE 1, one timepoint
- Retatrutide 4 mg, TRIUMPH-1, one timepoint
- Retatrutide 9 mg, TRIUMPH-1, one timepoint
- Retatrutide 12 mg, TRIUMPH-1, one timepoint
- Retatrutide Placebo, TRIUMPH-1, one timepoint
- Survodutide 3.6 mg, SYNCHRONIZE-1, one timepoint
- Survodutide 6.0 mg, SYNCHRONIZE-1, one timepoint
- Survodutide Placebo, SYNCHRONIZE-1, one timepoint
- VK2735 2.5 mg, VENTURE, one timepoint
- VK2735 15 mg, VENTURE, one timepoint
- VK2735 Placebo 13 weeks, VENTURE, one timepoint
- Eloralintide Placebo, NCT06230523, one timepoint
- Eloralintide 1 mg, NCT06230523, one timepoint
- Eloralintide 3 mg, NCT06230523, one timepoint
- Eloralintide 6 mg, NCT06230523, one timepoint
- Eloralintide 9 mg, NCT06230523, one timepoint
- Exenatide Exenatide once weekly (EQW ), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
- Exenatide Dapagliflozin (DAPA), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
- Exenatide EQW plus DAPA, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
- Exenatide Dapagliflozin plus Glucophage (MET ER), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
- Exenatide Phentermine /Topiramate (PHEN/ TPM) ER, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS), one timepoint
- Exenatide Exenatide once weekly extended-release, ECHO, one timepoint
- Exenatide Matching placebo, ECHO, one timepoint
- Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, one timepoint
- Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, one timepoint
- Liraglutide Liraglutide Placebo, no Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes, one timepoint
- Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, one timepoint
- Liraglutide 1.8 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, one timepoint
- Liraglutide Placebo, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes, one timepoint
- Liraglutide Metformin XR plus liraglutide, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM), one timepoint
- Liraglutide Metformin XR plus placebo, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM), one timepoint
- Liraglutide Liraglutide Pen Injector (Saxenda), SAXAPCOS, one timepoint
- Liraglutide Placebo liraglutide pen injector, SAXAPCOS, one timepoint
- Mazdutide 10 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
- Mazdutide 16 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
- Mazdutide Placebo, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
- Mazdutide 6 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight, one timepoint
- Setmelanotide Pivotal Cohort, Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity, one timepoint
- Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity, one timepoint
- Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity, one timepoint
- Setmelanotide Stage 1: Setmelanotide (Open-Label), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway, one timepoint
An arm with one reported week is a labeled point. It is not connected to zero.
Show as table
| Arm | Week | Change in body weight, % | Estimand |
|---|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | 68 | -14.9 | itt |
| Semaglutide Semaglutide placebo, STEP 1 | 68 | -2.4 | itt |
| Semaglutide 7.2 mg, STEP UP | 72 | -18.8 | itt |
| Semaglutide 2.4 mg, STEP UP | 72 | -15.5 | itt |
| Semaglutide Placebo, STEP UP | 72 | -3.9 | itt |
| Semaglutide Semaglutide, STEP 4 | 20 | -8.3 | efficacy |
| Semaglutide Placebo, STEP 4 | 20 | 6.5 | efficacy |
| Tirzepatide Placebo, SURMOUNT-1 | 72 | -3.1 | itt |
| Tirzepatide 5 mg, SURMOUNT-1 | 72 | -15 | itt |
| Tirzepatide 10 mg, SURMOUNT-1 | 72 | -19.5 | itt |
| Tirzepatide 15 mg, SURMOUNT-1 | 72 | -20.9 | itt |
| Cagrilintide/semaglutide cagrilintide 2.4 mg and semaglutide 2.4 mg, REDEFINE 1 | 68 | -20.4 | n/r |
| Cagrilintide/semaglutide Placebo s.c., REDEFINE 1 | 68 | -3 | n/r |
| Retatrutide 4 mg, TRIUMPH-1 | 80 | -17.6 | itt |
| Retatrutide 9 mg, TRIUMPH-1 | 80 | -23.7 | itt |
| Retatrutide 12 mg, TRIUMPH-1 | 80 | -25 | itt |
| Retatrutide Placebo, TRIUMPH-1 | 80 | -3.9 | itt |
| Survodutide 3.6 mg, SYNCHRONIZE-1 | 76 | -12.2 | itt |
| Survodutide 6.0 mg, SYNCHRONIZE-1 | 76 | -13 | itt |
| Survodutide Placebo, SYNCHRONIZE-1 | 76 | -5.4 | itt |
| VK2735 2.5 mg, VENTURE | 13 | -9.1 | n/r |
| VK2735 15 mg, VENTURE | 13 | -14.7 | n/r |
| VK2735 Placebo 13 weeks, VENTURE | 13 | -1.7 | n/r |
| Eloralintide Placebo, NCT06230523 | 48 | -0.4 | efficacy |
| Eloralintide 1 mg, NCT06230523 | 48 | -9 | efficacy |
| Eloralintide 3 mg, NCT06230523 | 48 | -12 | efficacy |
| Eloralintide 6 mg, NCT06230523 | 48 | -18 | efficacy |
| Eloralintide 9 mg, NCT06230523 | 48 | -20 | efficacy |
| Exenatide Exenatide once weekly (EQW ), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | 24 | 3.8 | n/r |
| Exenatide Dapagliflozin (DAPA), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | 24 | 1.5 | n/r |
| Exenatide EQW plus DAPA, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | 24 | 6.9 | n/r |
| Exenatide Dapagliflozin plus Glucophage (MET ER), EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | 24 | 1.7 | n/r |
| Exenatide Phentermine /Topiramate (PHEN/ TPM) ER, EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | 24 | 8.1 | n/r |
| Exenatide Exenatide once weekly extended-release, ECHO | 36 | 1.7 | n/r |
| Exenatide Matching placebo, ECHO | 36 | 3.5 | n/r |
| Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | 56 | 0.69 | n/r |
| Liraglutide 3.0mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | 56 | 2.91 | n/r |
| Liraglutide Liraglutide Placebo, no Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | 56 | 0.28 | n/r |
| Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | 56 | 2.3 | n/r |
| Liraglutide 1.8 mg, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | 56 | 2 | n/r |
| Liraglutide Placebo, Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | 56 | -0.1 | n/r |
| Liraglutide Metformin XR plus liraglutide, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | 84 | -7.2 | n/r |
| Liraglutide Metformin XR plus placebo, Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | 84 | -3.1 | n/r |
| Liraglutide Liraglutide Pen Injector (Saxenda), SAXAPCOS | 32 | 5.7 | n/r |
| Liraglutide Placebo liraglutide pen injector, SAXAPCOS | 32 | 1.4 | n/r |
| Mazdutide 10 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | 32 | 96.1 | n/r |
| Mazdutide 16 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | 32 | 92.23 | n/r |
| Mazdutide Placebo, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | 32 | 23.97 | n/r |
| Mazdutide 6 mg, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | 32 | 67.64 | n/r |
| Setmelanotide Pivotal Cohort, Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | 52 | -5.21 | n/r |
| Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | 52 | -12.34 | n/r |
| Setmelanotide Setmelanotide, Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity | 52 | -25.83 | n/r |
| Setmelanotide Stage 1: Setmelanotide (Open-Label), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway | 16 | -3.94 | n/r |
Not shown
- Semaglutide Semaglutide, SELECT: no timepoint reported
- Semaglutide Placebo (semaglutide), SELECT: no timepoint reported
- Semaglutide 1.0 mg, STEP 2: no timepoint reported
- Semaglutide 2.4 mg, STEP 2: no timepoint reported
- Semaglutide Semaglutide placebo I/II, STEP 2: endpoint not reported
- Semaglutide 2.4 mg, STEP 4: no timepoint reported
- Semaglutide Placebo, in trial, STEP 4: no timepoint reported
- Semaglutide 15 mg, SURMOUNT-5: endpoint not reported
- Semaglutide 2.4 mg, SURMOUNT-5: endpoint not reported
- Semaglutide 2.4 mg, STEP HFpEF DM: no timepoint reported
- Semaglutide Semaglutide placebo OW, STEP HFpEF DM: no timepoint reported
- Semaglutide Semaglutide, STEP 3: no timepoint reported
- Semaglutide Semaglutide placebo, STEP 3: no timepoint reported
- Semaglutide 2.4 mg, STEP 3: no timepoint reported
- Semaglutide Placebo, in trial, STEP 3: no timepoint reported
- Semaglutide Insuline glargine U100 (reduced) + semaglutide, A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S: endpoint not reported
- Semaglutide Insuline glargine U100 (titrated), A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S: endpoint not reported
- Semaglutide Semaglutide, STEP-HFpEF: no timepoint reported
- Semaglutide Placebo (semaglutide), STEP-HFpEF: no timepoint reported
- Semaglutide 7.2 mg, A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight: no timepoint reported
- Semaglutide 2.4 mg, A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight: no timepoint reported
- Semaglutide Placebo, A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight: no timepoint reported
- Semaglutide 2.4 mg, Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis: no timepoint reported
- Semaglutide 2.4 mg, Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis: no timepoint reported
- Semaglutide 2.4 mg, STEP 6: no timepoint reported
- Semaglutide 2.4 mg, STEP 6: no timepoint reported
- Semaglutide 1.7 mg, STEP 6: no timepoint reported
- Semaglutide 1.7 mg, STEP 6: endpoint not reported
- Semaglutide Semaglutide, STEP7: no timepoint reported
- Semaglutide Placebo (semaglutide), STEP7: no timepoint reported
- Semaglutide Semaglutide, STEP 5: no timepoint reported
- Semaglutide Placebo, STEP 5: no timepoint reported
- Semaglutide 2.4 mg, STEP 5: no timepoint reported
- Semaglutide Placebo, in trial, STEP 5: no timepoint reported
- Semaglutide Placebo, STEP12: no timepoint reported
- Semaglutide 2.4 mg, STEP12: no timepoint reported
- Semaglutide Semaglutide, STEP 10: no timepoint reported
- Semaglutide Placebo (semaglutide), STEP 10: no timepoint reported
- Semaglutide Semaglutide, A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity: no timepoint reported
- Semaglutide Placebo, A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity: no timepoint reported
- Semaglutide 2.4 mg, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
- Semaglutide Placebo, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
- Semaglutide Semaglutide, on treatment, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
- Semaglutide Placebo, on treatment, Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity: no timepoint reported
- Tirzepatide 15 mg, SURMOUNT-2: endpoint not reported
- Tirzepatide Placebo, SURMOUNT-2: endpoint not reported
- Tirzepatide 10 mg, SURMOUNT-2: endpoint not reported
- Tirzepatide Tirzepatide (lead-in), SURMOUNT-4: endpoint not reported
- Tirzepatide Tirzepatide MTD, SURMOUNT-4: endpoint not reported
- Tirzepatide Placebo, SURMOUNT-4: endpoint not reported
- Tirzepatide Tirzepatide, A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial: endpoint not reported
- Tirzepatide Placebo, A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial: endpoint not reported
- Tirzepatide Tirzepatide, SURMOUNT-3: endpoint not reported
- Tirzepatide Placebo, SURMOUNT-3: endpoint not reported
- Tirzepatide Tirzepatide MTD_GPI1, SURMOUNT-OSA: endpoint not reported
- Tirzepatide Placebo_GPI1, SURMOUNT-OSA: endpoint not reported
- Tirzepatide Tirzepatide MTD_GPI2, SURMOUNT-OSA: endpoint not reported
- Tirzepatide Placebo_GPI2, SURMOUNT-OSA: endpoint not reported
- Tirzepatide 15 mg, SURMOUNT-J: endpoint not reported
- Tirzepatide Placebo, SURMOUNT-J: endpoint not reported
- Tirzepatide 10 mg, SURMOUNT-J: endpoint not reported
- Tirzepatide 15 mg, SURMOUNT-CN: endpoint not reported
- Tirzepatide Placebo, SURMOUNT-CN: endpoint not reported
- Tirzepatide 10 mg, SURMOUNT-CN: endpoint not reported
- Orforglipron Placebo, ATTAIN-2: endpoint not reported
- Orforglipron 6 mg, ATTAIN-2: endpoint not reported
- Orforglipron 12 mg, ATTAIN-2: endpoint not reported
- Orforglipron Placebo QD, ATTAIN-J: endpoint not reported
- Orforglipron 6 mg, ATTAIN-J: endpoint not reported
- Orforglipron 12 mg, ATTAIN-J: endpoint not reported
- Survodutide 0.6 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
- Survodutide Placebo group, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
- Survodutide 2.4 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
- Survodutide 3.6 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
- Survodutide 4.8 mg, A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight: endpoint not reported
- Berobenatide Placebo, VESPER-1: endpoint not reported
- Dulaglutide Dulaglutide Arm, Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients: endpoint not reported
- Dulaglutide Placebo Arm, Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients: endpoint not reported
- Exenatide Group A, Effect on Weight Loss of Exenatide Versus Placebo: endpoint not reported
- Exenatide Group B, Effect on Weight Loss of Exenatide Versus Placebo: endpoint not reported
- Exenatide Exenatide, The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects: endpoint not reported
- Exenatide Placebo, The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects: endpoint not reported
- Exenatide Group A, A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients: endpoint not reported
- Exenatide Group B, A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients: endpoint not reported
- Liraglutide Liraglutide Placebo, Pre-diabetes, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes: no timepoint reported
- Liraglutide 3.0 mg, Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes: no timepoint reported
- Liraglutide 3.0 mg, Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance: endpoint not reported
- Liraglutide Placebo, Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance: endpoint not reported
- Liraglutide 3.0 mg, SCALE™ Insulin: no timepoint reported
- Liraglutide Placebo, SCALE™ Insulin: no timepoint reported
- Liraglutide 3.0 mg, Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea: endpoint not reported
- Liraglutide Placebo, Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea: endpoint not reported
- Liraglutide Semaglutide, STEP 8: no timepoint reported
- Liraglutide Liraglutide, STEP 8: no timepoint reported
- Liraglutide Placebo (liraglutide), STEP 8: no timepoint reported
- Liraglutide Liraglutide, SCALE™ IBT: no timepoint reported
- Liraglutide Placebo, SCALE™ IBT: no timepoint reported
- Liraglutide 3.0 mg, SCALE™ IBT: endpoint not reported
- Liraglutide Placebo, in trial, SCALE™ IBT: endpoint not reported
- Liraglutide Liraglutide, Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity: no timepoint reported
- Liraglutide Placebo, Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity: no timepoint reported
- Liraglutide Liraglutide, Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome: no timepoint reported
- Liraglutide Placebo, Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome: no timepoint reported
- Liraglutide 0.05 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
- Liraglutide 0.1 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
- Liraglutide 0.2 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
- Liraglutide 0.3 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
- Liraglutide 0.4 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
- Liraglutide 3.0 mg, Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus: endpoint not reported
- Liraglutide Placebo + Metformin, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
- Liraglutide Liraglutide + Metformin, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
- Liraglutide 100 mcg, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
- Liraglutide 200 mcg, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
- Liraglutide 300 mcg, A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes: endpoint not reported
- Liraglutide 2.4 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 4.5 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 1.2 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 0.6 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 0.3 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 3.0 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 3.0 mg, Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.: no timepoint reported
- Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
- Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
- Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
- Liraglutide 3.0 mg, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
- Liraglutide Orlistat, The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: endpoint not reported
- Lixisenatide Lixisenatide, 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years: endpoint not reported
- Lixisenatide Sitagliptin, 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years: endpoint not reported
- Mazdutide 3/6 Milligrams (mg) Mazdutide, A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight: endpoint not reported
- Oral Semaglutide Oral semaglutide, OASIS 1: no timepoint reported
- Oral Semaglutide Oral semaglutide placebo, OASIS 1: no timepoint reported
- Oral Semaglutide 25 mg, OASIS 4: no timepoint reported
- Oral Semaglutide Oral semaglutide placebo, OASIS 4: no timepoint reported
- Oral Semaglutide 50 mg, OASIS 2: no timepoint reported
- Oral Semaglutide oral semaglutide placebo once daily, OASIS 2: no timepoint reported
- TERN-601 250 mg, FALCON: endpoint not reported
- TERN-601 500 mg, FALCON: endpoint not reported
- TERN-601 750 mg, FALCON: endpoint not reported
- TERN-601 Matching Placebo, FALCON: endpoint not reported
- CT-868 CT-868 Placebo, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
- CT-868 1.8 mg, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
- CT-868 4.1 mg, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
- CT-868 6.6 mg, A Study of CT-868 in Type 1 Diabetes Mellitus: endpoint not reported
- HM15211 HM15211, A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD: endpoint not reported
- HM15211 Placebo, A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD: endpoint not reported
- Pramlintide Placebo-P + Placebo-M, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 360 mcg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 5.0 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 2.5 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 5.0 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 1.25 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 2.5 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 5.0 mg, Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects: endpoint not reported
- Pramlintide 1, Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin: endpoint not reported
- Pramlintide 2, Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin: endpoint not reported
- Pramlintide 3, Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin: endpoint not reported
- Pramlintide Placebo, A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects: no timepoint reported
- Pramlintide Pramlintide + Metreleptin, A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects: no timepoint reported
- Pramlintide Pramlintide Acetate and Placebo, A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects: endpoint not reported
- Pramlintide Lead-In Period, A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects: endpoint not reported
- Bimagrumab 30 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Bimagrumab 30 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Bimagrumab 30 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Bimagrumab 1.0 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Bimagrumab 2.4 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Bimagrumab 1.0 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Bimagrumab 2.4 mg, Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese: endpoint not reported
- Naltrexone And Bupropion NB16, A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects: endpoint not reported
- Naltrexone And Bupropion NB32, A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects: endpoint not reported
- Naltrexone And Bupropion Placebo, A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects: endpoint not reported
- Naltrexone And Bupropion NB32, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects: endpoint not reported
- Naltrexone And Bupropion Placebo, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects: endpoint not reported
- Naltrexone And Bupropion NB32, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program: endpoint not reported
- Naltrexone And Bupropion Placebo, A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program: endpoint not reported
- Naltrexone And Bupropion NB32, A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes: endpoint not reported
- Naltrexone And Bupropion Placebo, A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes: endpoint not reported
- Naltrexone And Bupropion BWL + NB medication, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment: endpoint not reported
- Naltrexone And Bupropion BWL + Placebo, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment: endpoint not reported
- Naltrexone And Bupropion Behavioral Weight Loss (BWL) + Naltrexone and Bupropion (NB) medication, Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1): endpoint not reported
- Naltrexone And Bupropion BWL + Placebo, Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1): endpoint not reported
- Naltrexone And Bupropion NB medication, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy: endpoint not reported
- Naltrexone And Bupropion Placebo, Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy: endpoint not reported
- Naltrexone And Bupropion Naltrexone+Bupropion Medication, Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a): endpoint not reported
- Naltrexone And Bupropion Placebo, Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a): endpoint not reported
- Naltrexone And Bupropion Naltrexone/Bupropion, Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders: endpoint not reported
- Naltrexone And Bupropion Placebo, Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders: endpoint not reported
- Orlistat Intensive Lifestyle Mod. Intervention, FIT-PLESE: endpoint not reported
- Orlistat Standard Lifestyle Intervention, FIT-PLESE: endpoint not reported
- Orlistat Placebo, Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases: endpoint not reported
- Orlistat Orlistat, Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases: endpoint not reported
- Phentermine And Topiramate VI-0521 Low, Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate VI-0521 Top, Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate Placebo, Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate VI-0521 Top, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate VI-0521 Mid, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate TPM 46, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate TPM 92, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate PHEN 7.5, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate PHEN 15, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate Placebo, A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults: endpoint not reported
- Phentermine And Topiramate LSMT 12, SMART: endpoint not reported
- Phentermine And Topiramate LSMT 24, SMART: endpoint not reported
- Phentermine And Topiramate Phentermine & Topiramate, Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds: endpoint not reported
- Phentermine And Topiramate Placebo Drugs, Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds: endpoint not reported
- Phentermine And Topiramate Semaglutide, A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America: no timepoint reported
- Phentermine And Topiramate Other anti-obesity medication, A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America: no timepoint reported
- Setmelanotide Setmelanotide, Long Term Extension Trial of Setmelanotide: endpoint not reported
- Setmelanotide Placebo, A Trial of Setmelanotide in Acquired Hypothalamic Obesity: endpoint not reported
- Setmelanotide Setmelanotide, A Trial of Setmelanotide in Acquired Hypothalamic Obesity: endpoint not reported
- Setmelanotide Setmelanotide (Double-Blind), Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: endpoint not reported
- Setmelanotide Placebo (Double-Blind), Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: endpoint not reported
- Setmelanotide Setmelanotide (Open-label), Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity: endpoint not reported
- Setmelanotide 2 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 2.5 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 3 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 20 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 25 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 3 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 30 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 20 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 25 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide 30 mg, Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway: endpoint not reported
- Setmelanotide Setmelanotide: PPL Group, Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity: endpoint not reported
- Setmelanotide Setmelanotide: BBS Group, Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity: endpoint not reported
- Setmelanotide 16p11.2 Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide AS Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide BBS Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide MC4R Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide POMC/PCSK1/LEPR Heterozygous Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide POMC/PCSK1/LEPR Composite Heterozygous Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide POMC/PCSK1/LEPR Compound Heterozygous Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide SH2B1 Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide SMS Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide SRC1 Cohort, Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity: no timepoint reported
- Setmelanotide Stage 2: Setmelanotide (Double-Blind), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: endpoint not reported
- Setmelanotide Stage 2: Placebo (Double-Blind), DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway: endpoint not reported
- Setmelanotide Placebo, Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients: endpoint not reported
- Setmelanotide Setmelanotide, Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants: no timepoint reported
- Setmelanotide Placebo, Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants: no timepoint reported
- Setmelanotide 0.5 mg, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: endpoint not reported
- Setmelanotide 1.5 mg, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: no timepoint reported
- Setmelanotide 2.5 mg, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: no timepoint reported
- Setmelanotide Placebo, Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome: endpoint not reported
- Sibutramine Sibutramine, SCOUT: endpoint not reported
- Sibutramine Placebo, SCOUT: endpoint not reported
- Tesofensine placebo arm, 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO): endpoint not reported
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.